JPRN-jRCT2080220922UnknownPhase 2
Phase 2 study of KRN125 (A dose finding study of KRN125 for chemotherapy-induced neutropenia in breast cancer)
Kyowa Hakko Kirin Co., Ltd.0 sitesStarted: November 20, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 65age old (—)
- Sex
- Female
Inclusion Criteria
- •Written informed consent
- •Diagnosed with stage II/III primary invasive breast cancer
- •No prior chemotherapy
- •Going to receive TAC treatment regimen as adjuvant or neoadjuvant chemotherapy
- •ECOG PS =< 2
- •Appropriate bone marrow, hepatic, renal, and heart functions
Exclusion Criteria
- •Complication or anamnesis of cardiac disease, such as heart failure and severe arrhythmia
- •Double cancer
- •Primary hematologic disease such as myelodysplastic syndrome or aplastic anemia
- •Undergoing interstitial pneumonia treatment
- •Previous radiotherapy within 4 weeks of enrollment
Investigators
Similar Trials
Unknown
Phase 2
K-115 phase 2 dose-respopnse studyPOAG or OHJPRN-jRCT2080220982Kowa Co., Ltd.200
Unknown
Phase 2
A phase 2 dose exploratory study of K-877DyslipidemiaJPRN-jRCT2080221294Kowa Co., Ltd.192
Unknown
Phase 1
A phase I study of NK105 administrated weekly in patients with advanced solid malignancies.JPRN-jRCT2080221196ippon Kayaku Co., Ltd.25
Unknown
Phase 3
A phase III, clinical study of KRN125JPRN-jRCT2080221502Kyowa Hakko Kirin Co., Ltd.
Active, not recruiting
Phase 1
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)EUCTR2021-001838-19-ESKeros Therapeutics, Inc.104